Login to Your Account



Basilea's J&J Agreement Worth Up To CHF370M; Stock Moves

By Cormac Sheridan


Wednesday, February 9, 2005
Basilea Pharmaceutica AG entered a worldwide agreement with Johnson & Johnson subsidiary Cilag AG International for the development, manufacturing and marketing of its cephalosporin antibiotic ceftobiprole, which is undergoing a Phase III trial in patients with complicated skin and skin-structure infections. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription